{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:21:22Z","timestamp":1793298082021,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) plays a central role in regulating low-density lipoprotein cholesterol (LDL-C) levels and has emerged as an attractive target for atherosclerotic cardiovascular disease (ASCVD) therapy. While mono\u00adclonal antibodies targeting PCSK9 have demonstrated clinical efficacy, their high cost and need for repeated administration limit widespread use. In this study, we developed a peptide-based vaccine by identifying B-cell epitopes from PCSK9\u2013antibody complexes using the Protein Data Bank (PDB) structural data and AlphaFold3 prediction, and fusing them with a heterologous T-helper epitope. The vaccine induced strong and durable anti-PCSK9 antibody responses in mice, guinea pigs, and rhesus macaques when formulated with the CpG plus alum adjuvant. The vaccine significantly reduced LDL-C levels and attenuated hepatic lipid accumulation in both prophylactic and therapeutic mouse models. Moreover, it mitigated the progression of atherosclerotic plaques. The vaccine also demonstrated no signs of systemic toxicity or autoimmunity in animal models. These findings indicate that the vaccine is a safe, effective, and scalable approach for controlling hypercholesterolemia and preventing ASCVD through active immunization against PCSK9.<\/jats:p>","DOI":"10.1093\/lifemeta\/loag013","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:39:15Z","timestamp":1779536355000},"source":"Crossref","is-referenced-by-count":2,"title":["Structure-guided design of a PCSK9 epitope vaccine with efficacy against hyperlipidemia and atherosclerosis"],"prefix":"10.1093","volume":"5","author":[{"given":"Hongliang","family":"Sun","sequence":"first","affiliation":[{"name":"College of Future Technology, Peking University , Beijing 100871,","place":["China"]},{"name":"Vaccine Division I, Changchun Institute of Biological Products Co., Ltd , Changchun, Jilin 130012,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[{"name":"First Research Laboratory, Changchun Institute of Biological Products Co., Ltd , Changchun, Jilin 130012,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Hu","sequence":"additional","affiliation":[{"name":"College of Future Technology, Peking University , Beijing 100871,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Scientific Research Management, Peking Institute of Biological Products Co., Ltd , Beijing 100176,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Ma","sequence":"additional","affiliation":[{"name":"Vaccine Division I, Changchun Institute of Biological Products Co., Ltd , Changchun, Jilin 130012,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory Animal Department, Changchun Institute of Biological Products Co., Ltd , Changchun, Jilin 130012,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Vaccine Division I, Changchun Institute of Biological Products Co., Ltd , Changchun, Jilin 130012,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiping","family":"Xiao","sequence":"additional","affiliation":[{"name":"College of Future Technology, Peking University , Beijing 100871,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026070200314219700_loag013-B1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u22122019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026070200314219700_loag013-B2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/JCN.0000000000001200","article-title":"The global burden of cardiovascular disease in adults: a mapping review","volume":"40","author":"Victor","year":"2025","journal-title":"J Cardiovasc Nurs"},{"key":"2026070200314219700_loag013-B3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026070200314219700_loag013-B4","first-page":"949","article-title":"Report on cardiovascular health and diseases in China 2023: an updated summary","volume":"37","author":"Center for Cardiovascular Diseases. The Writing Committee of the Report on Cardiovascular Health Diseases in China","year":"2024","journal-title":"Biomed Environ Sci"},{"key":"2026070200314219700_loag013-B5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/endrev\/bnae031","article-title":"The biology and clinical implications of PCSK7","volume":"46","author":"Sachan","year":"2025","journal-title":"Endocr Rev"},{"key":"2026070200314219700_loag013-B6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr Rev"},{"key":"2026070200314219700_loag013-B7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen JC, Boerwinkle E, Mosley TH Jr.","year":"2006","journal-title":"N Engl J Med"},{"key":"2026070200314219700_loag013-B8","doi-asserted-by":"crossref","first-page":"e001710","DOI":"10.1136\/openhrt-2021-001710","article-title":"Protective lipid-lowering variants in healthy older individuals without coronary heart disease","volume":"8","author":"Lacaze","year":"2021","journal-title":"Open Heart"},{"key":"2026070200314219700_loag013-B9","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol Ther"},{"key":"2026070200314219700_loag013-B10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention","volume":"23","author":"Michaeli","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026070200314219700_loag013-B11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2026070200314219700_loag013-B12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2026070200314219700_loag013-B13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","article-title":"Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"3","author":"Qi","year":"2023","journal-title":"JACC Asia"},{"key":"2026070200314219700_loag013-B14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study","volume":"147","author":"P\u00e9rez de Isla","year":"2023","journal-title":"Circulation"},{"key":"2026070200314219700_loag013-B15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070200314219700_loag013-B16","doi-asserted-by":"crossref","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2026070200314219700_loag013-B17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070200314219700_loag013-B18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/21556660.2020.1801452","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update","volume":"9","author":"Kaddoura","year":"2020","journal-title":"J Drug Assess"},{"key":"2026070200314219700_loag013-B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000877","article-title":"Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent","volume":"34","author":"Giordano","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"2026070200314219700_loag013-B20","doi-asserted-by":"crossref","first-page":"1158274","DOI":"10.3389\/fphar.2023.1158274","article-title":"Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026070200314219700_loag013-B21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40273-015-0355-y","article-title":"PCSK9 inhibitors: a technology worth paying for?","volume":"34","author":"Weintraub","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2026070200314219700_loag013-B22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2020.09.040","article-title":"Why and how vaccines work","volume":"183","author":"Iwasaki","year":"2020","journal-title":"Cell"},{"key":"2026070200314219700_loag013-B23","doi-asserted-by":"crossref","first-page":"114285","DOI":"10.1016\/j.celrep.2024.114285","article-title":"Cholesterol reduction by immunization with a PCSK9 mimic","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep"},{"key":"2026070200314219700_loag013-B24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"2026070200314219700_loag013-B25","first-page":"406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front Immunol"},{"key":"2026070200314219700_loag013-B26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: a case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2026070200314219700_loag013-B27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019hagan","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"2026070200314219700_loag013-B28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2007.01.002","article-title":"Modulation of mRNA stability as a novel therapeutic approach","volume":"114","author":"Eberhardt","year":"2007","journal-title":"Pharmacol Ther"},{"key":"2026070200314219700_loag013-B29","doi-asserted-by":"crossref","first-page":"101614","DOI":"10.1016\/j.xcrm.2024.101614","article-title":"Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia","volume":"5","author":"Fang","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026070200314219700_loag013-B30","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/eurheartj\/ehab299","article-title":"PCSK9 vaccine: so near, yet so far!","volume":"42","author":"Sahebkar","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070200314219700_loag013-B31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41541-023-00743-6","article-title":"A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates","volume":"8","author":"Fowler","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026070200314219700_loag013-B32","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"2026070200314219700_loag013-B33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/vaccines11010002","article-title":"A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines","volume":"11","author":"Goksoyr","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2026070200314219700_loag013-B34","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines\u2014an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS One"},{"key":"2026070200314219700_loag013-B35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type\u00a09 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur Heart J"},{"key":"2026070200314219700_loag013-B36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10557-020-07041-6","article-title":"PCSK9Q\u03b2-003 vaccine attenuates atherosclerosis in apolipoprotein E-deficient mice","volume":"35","author":"Wu","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026070200314219700_loag013-B37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/vaccines12101181","article-title":"T-cell epitope-based vaccines: a promising strategy for prevention of infectious diseases","volume":"12","author":"Song","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026070200314219700_loag013-B38","doi-asserted-by":"crossref","first-page":"100497","DOI":"10.1016\/j.jlr.2024.100497","article-title":"VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys","volume":"65","author":"Vroom","year":"2024","journal-title":"J Lipid Res"},{"key":"2026070200314219700_loag013-B39","doi-asserted-by":"crossref","first-page":"2680160","DOI":"10.1155\/2017\/2680160","article-title":"Funda\u00admentals and methods for T- and B-cell epitope prediction","volume":"2017","author":"Sanchez-Trincado","year":"2017","journal-title":"J Immunol Res"},{"key":"2026070200314219700_loag013-B40","doi-asserted-by":"crossref","first-page":"bbac567","DOI":"10.1093\/bib\/bbac567","article-title":"Critical review of conformational B-cell epitope prediction methods","volume":"24","author":"Cia","year":"2023","journal-title":"Brief Bioinform"},{"key":"2026070200314219700_loag013-B41","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070200314219700_loag013-B42","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nsmb.3453","article-title":"Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists","volume":"24","author":"Zhang","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"2026070200314219700_loag013-B43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.187419","article-title":"Proprotein convertase substilisin\/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates","volume":"340","author":"Liang","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2026070200314219700_loag013-B44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41401-024-01429-y","article-title":"AlphaFold3 versus experimental structures: assessment of the accuracy in ligand-bound G protein-coupled receptors","volume":"46","author":"He","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"2026070200314219700_loag013-B45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/vaccines9070749","article-title":"Pre-clinical evaluation of the nanoliposomal antiPCSK9 vaccine in healthy non-human primates","volume":"9","author":"Momtazi-Borojeni","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2026070200314219700_loag013-B46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/jcm12010363","article-title":"Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies","volume":"12","author":"Du","year":"2023","journal-title":"J Clin Med"},{"key":"2026070200314219700_loag013-B47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"2026070200314219700_loag013-B48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41569-021-00634-0","article-title":"PCSK9-targeted therapies: present and future approaches","volume":"18","author":"Rifai","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026070200314219700_loag013-B49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"2026070200314219700_loag013-B50","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein data bank (PDB): the single global macromolecular structure archive","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2026070200314219700_loag013-B51","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"key":"2026070200314219700_loag013-B52","doi-asserted-by":"crossref","first-page":"D506\u2013","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","author":"Uniprot","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026070200314219700_loag013-B53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pro.3290","article-title":"Clustal omega for making accurate alignments of many protein sequences","volume":"27","author":"Sievers","year":"2018","journal-title":"Protein Sci"},{"key":"2026070200314219700_loag013-B54","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/bioinformatics\/btx469","article-title":"Ggseqlogo: a versatile R package for drawing sequence logos","volume":"33","author":"Wagih","year":"2017","journal-title":"Bioinformatics"}],"container-title":["Life Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/lifemeta\/advance-article-pdf\/doi\/10.1093\/lifemeta\/loag013\/68397513\/loag013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lifemeta\/article-pdf\/5\/4\/loag013\/68397513\/loag013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lifemeta\/article-pdf\/5\/4\/loag013\/68397513\/loag013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:31:58Z","timestamp":1782966718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/lifemeta\/article\/doi\/10.1093\/lifemeta\/loag013\/8694677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/lifemeta\/loag013","relation":{},"ISSN":["2755-0230"],"issn-type":[{"value":"2755-0230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,26]]},"article-number":"loag013"}}